Wrap Text
Notification: transactions by persons discharging managerial responsibilities & persons closely associated with them
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
("Mediclinic", the "Company", or the "Group")
7 June 2021
NOTIFICATION: TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES & PERSONS CLOSELY ASSOCIATED WITH THEM
This notification sets out the details of awards over ordinary shares in Mediclinic ("Shares") granted to
directors and other persons discharging managerial responsibilities ("PDMRs") on 4 June 2021 under
the Company’s short-term incentive scheme (the "STI") and long-term incentive plan (the "LTIP").
Awards granted under the Company's STI and LTIP
On 4 June 2021, awards over Shares were granted to the following directors and other PDMRs under
the Company’s STI and LTIP, in accordance with the remuneration policy approved by shareholders in
July 2020 (the "Remuneration Policy"):
Name Director/ Number of Number of Shares
PDMR Shares awarded under
awarded the LTIP
under the
FY21 STI
Dr Carel Aron van der Merwe Director 122 614 356 181
Petrus Jurgens Myburgh Director 80 655 190 569
David John Hadley PDMR n/a 122 259
Gert Cornelis Hattingh PDMR n/a 72 993
Dr Dirk Cornelius le Roux PDMR n/a 57 158
Dr Daniel Liedtke PDMR n/a 118 270
Magnus Oetiker PDMR n/a 96 910
Koert Hendrik Stefanus Pretorius PDMR n/a 76 408
Dr René Toua PDMR n/a 59 487
Dr Tyson Bruno Welzel PDMR n/a 47 688
Awards under the STI and LTIP were granted for nil consideration and are based on the average of the
middle-market quotations of a Share during a period of five dealing days ending with the dealing day
before the day of grant, which equates to £3.35 per Share.
STI awards
The Remuneration Committee (the "Committee") considered at length the pay-out under the STI to the
executive directors in respect of the financial year ended 31 March 2021 ("FY21"), taking into account
financial and overall business performance and the experience of shareholders, employees and clients.
The performance delivered against the pre-defined adjusted EBIT target resulted in a pay-out of 100%
of a maximum bonus.
The Committee reviewed the clinical quality, client experience and employee engagement performance
for the Group and considered that the formulaic outcome was an appropriate reflection of the Group’s
overall performance, and the performance and leadership by the executives of the business through
COVID-19. However, the Committee was acutely aware that the dividend was likely to remain
suspended as part of the Group's broad response to maintaining its liquidity position, and as such,
determined that it would be appropriate for the release of the STI to be conditional on the Company’s
dividend being reinstated. The payment of the cash proportion of the FY21 STI (50%) was therefore
deferred until such time. The remaining 50% of the bonus award was deferred into shares, with the
awards subject to the reinstatement of the Company’s dividend as well as the usual two-year vesting
period and continued employment condition under the Remuneration Policy.
Further details on the Committee’s decision regarding the FY21 STI are set out in the Remuneration
Committee Report included in the Group’s Annual Report and Financial Statements for the year ended
31 March 2021 (the "FY21 Annual Report"), which will be published towards the end of June 2021.
LTIP awards
On 4 June 2021, the Committee also granted awards under the Company’s LTIP to the Group Chief
Executive Office and Group Chief Financial Officer with a face value equivalent to 200% and 150% of
salary, respectively (the "FY22 LTIP Awards"). The Committee considered it appropriate to grant
awards in line with the normal maximum levels under the Remuneration Policy taking into account share
price performance since the grant of FY21 LTIP Awards and the level of stretch included in the
performance targets. Awards were also granted to the other members of the Group Executive
Committee. The Committee will also use its discretion to amend the vesting outcome where it considers
that it is not representative of business performance. This includes consideration of any potential
‘windfall gains’ at the point of vesting.
Awards granted under the LTIP are structured as conditional awards, with vesting being subject to the
satisfaction of performance conditions over a three-year period. Awards granted to the executive
directors will be settled in shares upon vesting, and will be subject to a further two-year holding period.
Details of the performance conditions for the FY22 LTIP Awards are set out in the Remuneration
Committee Report included in the Group’s FY21 Annual Report.
1. Details of PDMR / person closely associated with them ("PCA")
a) Name Dr Carel Aron van der Merwe
2. Reason for the notification
a) Position / status Group Chief Executive Officer - Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4.1 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Short-Term Incentive
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 122 614
d) Aggregated
information
Aggregated volume 122 614
Price £nil
e) Date of the 4 June 2021
transaction
f) Place of the Outside a trading venue
transaction
4.2 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 356 181
d) Aggregated
information
Aggregated volume 356 181
Price £nil
e) Date of the 4 June 2021
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them ("PCA")
a) Name Petrus Jurgens Myburgh
2. Reason for the notification
a) Position / status Group Chief Financial Officer - Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4.1 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Short-Term Incentive
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 80 655
d) Aggregated
information
Aggregated volume 80 655
Price £nil
e) Date of the 4 June 2021
transaction
f) Place of the Outside a trading venue
transaction
4.2 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 190 569
d) Aggregated
information
Aggregated volume 190 569
Price £nil
e) Date of the 4 June 2021
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them ("PCA")
a) Name David John Hadley
2. Reason for the notification
a) Position / status Chief Executive Officer – Mediclinic Middle East
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 122 259
d) Aggregated
information
Aggregated volume 122 259
Price £nil
e) Date of the 4 June 2021
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them ("PCA")
a) Name Gert Cornelis Hattingh
2. Reason for the notification
a) Position / status Group Chief Governance Officer - Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 72 993
d) Aggregated
information
Aggregated volume 72 993
Price £nil
e) Date of the 4 June 2021
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them ("PCA")
a) Name Dr Dirk Cornelius le Roux
2. Reason for the notification
a) Position / status Group Chief Information Officer - Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 57 158
d) Aggregated
information
Aggregated volume 57 158
Price £nil
e) Date of the 4 June 2021
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them ("PCA")
a) Name Dr Daniel Liedtke
2. Reason for the notification
a) Position / status Chief Executive Officer: Hirslanden
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 118 270
d) Aggregated
information
Aggregated volume 118 270
Price £nil
e) Date of the 4 June 2021
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them ("PCA")
a) Name Magnus Oetiker
2. Reason for the notification
a) Position / status Group Chief Strategy and Human Resources Officer – Mediclinic
International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 96 910
d) Aggregated
information
Aggregated volume 96 910
Price £nil
e) Date of the 4 June 2021
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them ("PCA")
a) Name Koert Hendrik Stefanus Pretorius
2. Reason for the notification
a) Position / status Chief Executive Officer – Mediclinic Southern Africa
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 76 408
d) Aggregated
information
Aggregated volume 76 408
Price £nil
e) Date of the 4 June 2021
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them ("PCA")
a) Name Dr René Toua
2. Reason for the notification
a) Position / status Group Chief Clinical Officer - Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 59 487
d) Aggregated
information
Aggregated volume 59 487
Price £nil
e) Date of the 4 June 2021
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them ("PCA")
a) Name Dr Tyson Bruno Welzel
2. Reason for the notification
a) Position / status Group Chief Innovation Officer – Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 47 688
d) Aggregated
information
Aggregated volume 47 688
Price £nil
e) Date of the 4 June 2021
transaction
f) Place of the Outside a trading venue
transaction
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab
Emirates ("UAE").
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
its markets.
At 31 March 2021, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health
facilities, 18 day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and four day
case clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations
included 50 hospitals (three of which in Namibia), five sub-acute hospitals, two mental health facilities
and 12 day case clinics (four of which operated by Intercare) across South Africa, and around 8 600
inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18
outpatient clinics with more than 900 inpatient beds in the UAE. In addition, under management
contracts, Mediclinic Middle East operates one hospital in Abu Dhabi and will open a 200-bed hospital
in the Kingdom of Saudi Arabia in mid-2022.
The Company’s primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with
secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment
Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 07-06-2021 11:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
